The pathogenesis of the eosinophilia myalgia syndrome (EMS) remains unclear. Several abnormal constituents have been found in the L-tryptophan lots responsible for the illness, particularly, 1,1-ethylidenebis[L-tryptophan], also called peak E or EBT, and 3-phenylamino-alanine or peak 5. However, the role of these contaminants in the pathogenesis of EMS and in the development of fibrosis is unknown. We now report that peak E, a dimer of L-tryptophan, is a potent stimulus for human dermal fibroblast DNA and collagen synthesis. Peak E (0.1-1.0 jIM) increased DNA synthesis up to four-fold (P = 0.0001) in a dose-dependent manner (r = 0.987). When added to monolayer cultures for 2 to 24 h, peak E (0.5 to 100 ,uM) caused a progressive, more than threefold increase in alpha 1(I) procollagen mRNA levels and collagenous protein. No increase in procollagen mRNA levels was found after the addition of another major L-tryptophan contaminant, peak 5, or with L-tryptophan itself. Transient transfection with a 2.5-kb alpha 1(I) procollagen promoter-luciferase construct showed that peak E causes a twofold upregulation of promoter activity (P = 0.022). Contraction of collagen gels, consisting of human dermal fibroblasts incorporated into a type I collagen lattice, was enhanced two-fold by exposure to peak E (P = 0.001). We conclude that a major constituent of contaminated batches of L-tryptophan, peak E, is a potent stimulus for fibroblast activation and collagen synthesis. This stimulatory action of peak E may provide a direct mechanism for the development of fibrosis in EMS. (J. Clin. Invest. 1995. 96:2120-2125
Introduction
Eosinophilia myalgia syndrome (EMS) 1 is a newly recognized disease which occurred in an epidemic form from 1989 to 1991 and was found to be associated with the ingestion of altered Ltryptophan preparations. Although the initial defining features were myalgia and unexplained peripheral blood eosinophilia, it was later recognized that EMS involves many organ systems and leads to a variety of clinical presentations (1) (2) (3) . Approximately half the patients with EMS have developed cutaneous or internal organ fibrosis, often identical to that seen in several forms of scleroderma. Indeed, the clinical picture of many EMS patients closely resembles eosinophilic fasciitis (Shulman's syndrome) (4, 5) .
The pathogenesis of EMS remains unclear. Several abnormal constituents have been found in the L-tryptophan lots responsible for the illness, particularly 1, 1-ethylidenebis [L-tryp- tophan], also called peak E or EBT, and 3-phenylamino-alanine or peak 5 (6) (7) (8) . However, the role of these contaminants in the pathogenesis of EMS and in the development of fibrosis is unknown. Recent reports have focused on a pathogenic role of peak E, an unusual compound formed during the manufacturing of L-tryptophan and consisting of two tryptophan molecules joined by an ethylidene bridge between the two indole ring nitrogens. It has been shown that Lewis rats treated with peak E or with contaminated L-tryptophan develop immunopathological abnormalities and myofascial thickening (9) . Most recently, intraperitoneal administration of peak E in an experimental murine model has been shown to cause an inflammatory response and mast cell degranulation (10) . We have hypothesized that peak E has direct stimulatory effects on fibroblast replication and synthetic activity and that it may play an important direct role in the pathogenesis of fibrosis in EMS. The results shown here support this hypothesis.
Methods
Fibroblast cultures. Cultures of human dermal fibroblasts were established as previously described ( 11) from biopsies of dorsal forearm skin of adult healthy donors. Five different fibroblast strains in passages 3-8 were used throughout the experiments. For experiments involving transfection and collagen gels, we used neonatal foreskin fibroblasts in the first two in vitro passages. Cultures were initiated from explants and passaged in T-75 flasks (Coming glass works, Coming, NY) and seeded in DME (Sigma Chemical Co., St. Louis, MO) and 10% fetal bovine serum (FBS) (GIBCO Laboratories, Grand Island, NY). For experiments, FBS was substituted with dialyzed and L-tryptophan-free fetal calf serum (HyClone serum; HyClone Laboratories, Logan, UT). Unless otherwise indicated, all experiments involving collagen measurements were done in the presence of freshly prepared 100 itM ascorbic acid (Sigma Chemical Co.) added daily. Except when stated, experiments were carried out by replacing DME with RPMI free of L-tryptophan. Fibroblasts were grown and kept at 370C in 5% C02, 95% air. Experi-(Sigma Chemical Co.). After 24 h the monolayers were washed with L-tryptophan-free RPMI three times over two hours, at which time the experimental media were added. The experimental media tested included L-tryptophan (GIBCO BRL), peak E, and peak 5 (Showa Denko Co., Tokyo, Japan).
[3H]Thymidine uptake. Fibroblasts were seeded at 30,000 cells per 2 cm2 wells in DME supplemented with 10% FBS. After 24 h, monolayers were washed with phosphate buffered saline (PBS, GIBCO BRL) and the medium was replaced with 1 ml of DME and 0.5% HyClone serum. After an additional 24 h, monolayers were washed with PBS and incubated for 24 h with 1 ml of L-tryptophan-free RPMI, 0.5% Hyclone serum, and increasing concentrations of peak E (Showa Denko Co., Tokyo, Japan), which was prepared by dissolving it in 40 mM or either HCl or NaOH. The pH of the stock solution of peak E in HC1 was measured at 2.03, and this was quickly and completely neutralized to 7.34 by addition to culture media in the concentrations of peak E tested (0.1-100 AM). Next Transfection studies. The human alpha 1 (I) procollagen promoter-CAT construct was a generous gift from Dr. Francesco Ramirez (Mount Sinai University, New York, NY) and has been previously described (16, 17) . For these experiments, the construct was modified as follows. The 2.5-kb promoter region was excised with BamHI from the p8-CAT vector and inserted in the Bglll site of the polylinker region of the pGL2-Basic Vector (Promega, Madison, WI) immediately upstream of the luciferase gene. Proper construct orientation was determined by restriction enzyme analysis. The pGL2-Control Vector, which contains an SV-40 promoter and an SV-40 enhancer inserted into the structure of the pGL2-Basic Vector, served as a positive internal control for transfection. For transfection, neonatal foreskin fibroblasts (passage 2)
were first grown in DME and 10% PBS. The cells were then plated in 35-mm tissue culture dishes 24 h before transfection. Transfection was performed as previously described ( 18) . The optimal amount of plasmid DNA and lipofectin was determined empirically for each new lot of lipofectin and new plasmid DNA preparation. For these experiments, we used 2 Htg of plasmid DNA and 4 il of lipofectin (GIBCO BRL) diluted with ITS (Becton Dickinson Labware, Bedford, MA). 6 h later, the medium was changed to DME and 10% Hyclone serum. After overnight incubation, peak E (100 jAM) or control media were added for an additional 48 h. In other experiments, several concentrations of L-tryptophan were tested using the same experimental conditions. Cell extracts were prepared using a cell culture lysis reagent and a luciferase assay system (Promega) according to the manufacturer's protocol. Lu- Peak E (LM] Figure 1 . Peak E enhances DNA synthesis in human dermal fibroblasts.
[3H]Thymidine uptake was measured 24 
Results
The hypothesis tested in these experiments is that peak E is a direct stimulus for fibroblast activation. We first measured the effect of peak E on fibroblast DNA synthesis. As shown in Fig.  1 (Fig. 3 ) or collagen synthesis (Fig. 4) . Type I collagen is the major collagen found in adult dermis, and its production is increased in EMS skin (21) and by EMS fibroblasts (22) . In the next series of experiments, we found that exposure of fibroblasts to concentrations of peak E ranging from 0.5 to 100 ,M caused a dose-dependent (r = .817) more than threefold increase in alpha 1(I) procollagen mRNA levels (Fig.  5) . Upregulation of procollagen mRNA by peak E was found in four different experiments, was observed as early as two hours after the addition of peak E (Fig. 6) , and persisted at 24 h (Figs. 5 and 6). Peak 5, another major contaminant found in EMS-associated L-tryptophan, had no stimulatory effect on alpha 1(I) procollagen mRNA levels ( Fig. 7) . At the highest concentrations tested (100 uM), peak 5 actually caused a small decrease in procollagen mRNA levels (Fig. 7) . L-tryptophan itself and some of its normal metabolites have long been implicated in the pathogenesis of fibrosis, even before the EMS epidemic (4, 5) . We therefore measured the direct effects of Ltryptophan on alpha 1(I) procollagen mRNA levels. As in the representative experiment shown in Fig. 8 more reproducibly transfected than adult fibroblasts and still allow us to test the alpha 1(I) procollagen promoter region in relevant human cells. Fig. 9 shows that peak E enhanced promoter activity by almost twofold (P = 0.0226). The extent of stimulation of this alpha 1 (I) procollagen promoter region was comparable to that observed with the addition of 5 ng/ml of transforming growth factor-beta 1 (TGF-beta 1), which served as an additional positive control. As observed with DNA and collagen synthesis, increasing concentrations of L-tryptophan also failed to stimulate the activity of the alpha 1 (I) procollagen promoter (Fig. 10) . The above results show that peak E stimulates fibroblast DNA synthesis and collagen production. We next tested peak E in an in vitro model of fibrosis that is dependent on the ability of fibroblasts to contract a collagen lattice in which they are incorporated (20) . We prepared collagen lattices (gels) by seeding human dermal fibroblasts in a solution of type I collagen (20) . First, we determined the cell number (6.0 X 104 per ml) and serum concentration (10%) required for optimal gel contraction (data not shown). We then exposed collagen gels to either peak E or PDGF in 10% FBS. Platelet-derived growth factor BB (PDGF; 4 nM) was used as a positive internal control because this peptide growth factor is a known inducer of collagen gel contraction (23) . As shown in Fig. 11 , peak E increased gel contraction more than twofold by day 9 (P = 0.001). Between days 7 and 9 the effect of peak on collagen gel contraction was equivalent to that observed with PDGF (P > 0.05), although PDGF enhanced gel contraction at earlier time points with respect to both control and peak E (days 1 to 4; P < 0.01).
Discussion
A prominent feature of EMS has been the development of cutaneous and internal organ fibrosis. In situ hybridization studies have shown increased synthesis of several components of the extracellular matrix, including types I, III, and VI collagen in the affected dermis (21 ) . Enhanced transcription of alpha 1 (I) procollagen has been reported in fibroblast cultures established The results were obtained after 24 h of incubation with peak 5. from the fibrotic skin of EMS patients (22) . However, the pathogenesis of increased collagen synthesis in EMS remains unknown. In the present report, we have demonstrated that peak E, a prominent abnormal constituent of L-tryptophan preparations causing EMS, is a potent stimulus for DNA and collagen synthesis in cultures of normal human dermal fibroblasts. We found peak E to enhance DNA synthesis in a dose-dependent manner. As early as 2 h after its addition, peak E caused a dosedependent increase in collagenous protein and in alpha 1(I) procollagen mRNA levels. Conversely, L-tryptophan itself and peak 5, another prominent contaminant identified in EMS-associated L-tryptophan preparations, had no effect on procollagen mRNA levels. Peak E enhanced alpha 1(I) procollagen promoter activity and the contraction of collagen gels. Taken together, these results point to peak E as a potent and independently acting stimulus for fibroblast activation and collagen synthesis. Thus, peak E should be regarded as a possible pathogenic substance in the development of fibrosis in EMS. associated with EMS, and it apparently formed during a change in the manufacturing process of L-tryptophan (6) (7) (8) . Indeed, a close correlation has been found between the development of EMS and the presence of peak E in contaminated L-tryptophan preparations (8) . Lewis rats treated with EMS-associated Ltryptophan or with peak E develop several immunopathological abnormalities and significant myofascial thickening (9) . More recently, it has been shown that peak E administered intraperitoneally in an experimental murine model leads to mast cell activation (10) . Immunologic activation in response to peak E appears to occur at multiple levels. It has been shown that peak E leads to functional activation of eosinophils and interleukin 5 production by T-lymphocytes (28) . This present report complements these recent immunologic studies by documenting a direct fibroblast-activating role of peak E.
In conclusion, we have shown that peak E, a major abnormal constituent of L-tryptophan preparations linked to the development of EMS, upregulates DNA and collagen synthesis in cultures of normal human dermal fibroblasts. This observation may provide an additional direct mechanism of fibrosis in EMS.
cause disease in experimental animals and in patients with EMS (9, 10) .
For a number of years, even before the EMS epidemic, Ltryptophan and some of its normal metabolites, such as serotonin and kynurenine, have been implicated in the development of fibrosis (2, 4, 5) . Injection of serotonin in animals has led to increased collagen deposition (25). Patients with EMS have been shown to have increased plasma levels of kynurenine, possibly as a result of increased activity of the enzyme indoleamine 2,3-dioxygenase (IDO) (2) . Interestingly, supraphysiologic concentrations of L-tryptophan have been shown to stimulate collagenase synthesis and transcription in human skin fibroblasts (26) . More recently, experimental approaches have focused on reproducing fibrosis and other features of EMS in animals by the administration of peak E (9, 27) . Peak E is the most prominent abnormal constituent of L-tryptophan lots Figure 11 . Increased collagen gel contraction in response to peak E. Gels, consisting of type I collagen and human dermal fibroblasts, were incubated in the presence of 10% FBS (control) with either peak E or PDGF BB (additional control). Gel diameter was measured daily. The results are the mean+SD from quadruplicate wells.
